Literature DB >> 28184936

Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells.

Hui Xu1, Mingping Qian1, Bingkun Zhao1, Chenyang Wu1, Niraj Maskey1, Hongming Song1, Dengfeng Li1, Jialu Song1, Kaiyao Hua1, Lin Fang1.   

Abstract

RAB1A acts as an oncogene in various cancers, and emerging evidence has verified that RAB1A is an mTORC1 activator in hepatocellular and colorectal cancer, but the role of RAB1A in breast cancer remains unclear. In this investigation, RAB1A siRNA was successfully transfected in MDA-MB-231 and BT-549 human triple-negative breast cancer cells, and verified by real‑time quantitative polymerase chain reaction and western blotting. Then, MTT cell proliferation, colony formation, cell invasion and wound healing assays were performed to characterize the function of RAB1A in the breast cancer cell lines. Downregulation of RAB1A inhibited cellular growth, cell migration, cell invasion and cell epithelial-mesenchymal transition. Furthermore, compared with NC siRNA transfected cells, RAB1A siRNA transfected breast cancer cells inhibited the phosphorylation of S6K1, the effector molecular of mTORC1. Collectively, our data suggested that RAB1A acts as an oncogene by regulating cellular proliferation, growth, invasion and metastasis via activation of mTORC1 pathway in triple-negative breast cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28184936     DOI: 10.3892/or.2017.5404

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  17 in total

1.  Overexpression of PTEN suppresses non-small-cell lung carcinoma metastasis through inhibition of integrin αVβ6 signaling.

Authors:  Yan Xia Yu; Yi Wang; Hong Liu
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 2.  Consequences of Rab GTPase dysfunction in genetic or acquired human diseases.

Authors:  Marcellus J Banworth; Guangpu Li
Journal:  Small GTPases       Date:  2017-12-28

3.  [Effects of RAB1A on the proliferation, invasion, and metastasis of tongue squamous cell carcinoma cells].

Authors:  Xue-Hui Sun; Xin Fan; Kai-Li Hu; Wen-Ting Hu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

4.  Hypoxia-mediated miR-212-3p downregulation enhances progression of intrahepatic cholangiocarcinoma through upregulation of Rab1a.

Authors:  Panzhang Hou; Yi Kang; Jianchao Luo
Journal:  Cancer Biol Ther       Date:  2018-05-14       Impact factor: 4.742

5.  LncRNA DANCR functions as a competing endogenous RNA to regulate RAB1A expression by sponging miR-634 in glioma.

Authors:  Dawei Xu; Jian Yu; Guojun Gao; Guangjian Lu; Yi Zhang; Pengju Ma
Journal:  Biosci Rep       Date:  2018-02-02       Impact factor: 3.840

6.  Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.

Authors:  Zhengwu Cheng; Xinyu Shao; Menglin Xu; Junfeng Wang; Xiaoyi Kuai; Liping Zhang; Jian Wu; Chunli Zhou; Jiading Mao
Journal:  Oncol Rep       Date:  2019-03-15       Impact factor: 3.906

7.  miR‑139‑3p suppresses the invasion and migration properties of breast cancer cells by targeting RAB1A.

Authors:  Wei Zhang; Jing Xu; Ke Wang; Xiaojiang Tang; Jianjun He
Journal:  Oncol Rep       Date:  2019-08-29       Impact factor: 3.906

8.  Proteomic Characterization of Cytoplasmic Lipid Droplets in Human Metastatic Breast Cancer Cells.

Authors:  Alyssa S Zembroski; Chaylen Andolino; Kimberly K Buhman; Dorothy Teegarden
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

9.  Expression of Rab1A in bladder cancer and its clinical implications.

Authors:  Hongwei Su; Ting Li; Chen Li; Xin Liu; Haibin Ling; Xiangdong Li
Journal:  Exp Ther Med       Date:  2020-09-03       Impact factor: 2.447

10.  Expression analysis and implication of Rab1A in gastrointestinal relevant tumor.

Authors:  Menglin Xu; Xinyu Shao; Xiaoyi Kuai; Liping Zhang; Chunli Zhou; Zhengwu Cheng
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.